This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day.
Pharma Stock Roundup: FDA Gives Nod to RHHBY's Lunsumio, Accepts PFE Vaccine BLA
by Kinjel Shah
FDA approves Roche's (RHHBY) Lunsumio for follicular lymphoma and accepts Pfizer's (PFE) BLA for the pentavalent meningococcal vaccine candidate.
AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers
by Zacks Equity Research
The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.
Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer
by Zacks Equity Research
Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.
The Zacks Analyst Blog Highlights Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies
by Zacks Equity Research
Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies are part of the Zacks top Analyst Blog.
Top Research Reports for Novo Nordisk, AstraZeneca & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AstraZeneca PLC (AZN) and Accenture plc (ACN).
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.
AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs
by Zacks Equity Research
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Astrazeneca (AZN) Stock Moves -0.69%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $67.47, moving -0.69% from the previous trading session.
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
by Zacks Equity Research
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
by Zacks Equity Research
The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.
Implied Volatility Surging for AstraZeneca (AZN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AstraZeneca (AZN) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca
by Zacks Equity Research
Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 Large Drug Stocks to Watch in a Booming Industry
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
by Zacks Equity Research
Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.
Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy
by Zacks Equity Research
Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.
Novartis' (NVS) PNH Candidate Achieves Study Objectives
by Zacks Equity Research
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
by Kinjel Shah
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
by Zacks Equity Research
The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
by Zacks Equity Research
Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.